Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web.
La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias.
Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso.
En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web.
Más información en el apartado POLÍTICA DE COOKIES de nuestra página web.



Our medical oncologists and laboratory investigators are regular speakers and organizers of some of the most important international seminars and scientific meetings.

We have presented the results of our investigations into the causes of cancer and novel treatments at some of the most important national and international oncology congresses.


European Respiratory Congress



Understanding the mechanisms of TKIs: the cycle of inhibition and resistance: STAT3 and YAP-NOTCH signaling rebound as a compensatory response to gefitinib or osimertinib treatment in EGFR mutant lung cancer Rosell R.

Future Horizons in Lung Cancer

DATE01/09/2016 - 02/10/2016


Understanding the mechanisms of immunotherapy in lung cancer Rosell R.

International Symposium on Resolving Cancer Heterogeneity: The way to personalised medicine

DATE30/06/2016 - 02/07/2016

PLACEVerona, Italy

Future perspectives for treatment strategies in EGFR mutant NSCLC Rosell R, MD, PhD

First Cancer Cell Signaling Pathways Meeting: An In Depth Look at Trends in Poly-Targeted Lung Cancer Therapy


PLACEInstitut Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain

Moving forward in cancer Rosell R. MD, PhD

Intratumor heterogeneity in lung adenocarcinoma: Beyond the genes Ramon y Cajal S. MD, PhD

[return] Co-activation of signal transducer and activator of transcription 3 (STAT3) and YES-associated protein 1 (YAP1) pathway in EGFR mutant non-small-cell lung cancer Karachaliou N. MD, PhD

Cancer stem cells in EGFR mutant NSCLC Codony J. PhD, Codony C. PhD

Annual Meeting, American Society of Clinical Oncology (ASCO)

DATE03/06/2016 - 07/06/2016


Targeting RET in patients with RET-rearranged lung cancers: results from a global registry Oliver Gautschi, Juergen Wolf, Julien Mazieres, Julie Milia, Thomas Filleron, David Paul Carbone, Mark M. Awad, D. Ross Camidge, Benjamin Besse, Byoung Chul Cho, Pasi A. Janne, Florian Cabillic, Jin-Yuan Shih, Michel Van Den Heuvel, Nir Peled, Daniel D. Karp, Rafael Rosell, Mark G. Kris, Alexander E. Drilon, on behalf of the GLORY investigators. Poster #164061

Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): phase (ph) 1/2 trial results Corey J. Langer, Scott N. Gettinger, Lyudmila Bazhenova, Ravi Salgia, Kathryn A. Gold, Rafael Rosell, Alice Tsang Shaw, Glen J. Weiss, David J. Dorer, Victor M. Rivera, Frank G. Haluska, David Kerstein, D. Ross Camidge. Poster #164989

Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status Author(s): Scott N. Gettinger, Sen Zhang, J. Graeme Hodgson, Lyudmila Bazhenova, Sjaak Burgers, Dong-Wan Kim, Daniel Shao-Weng Tan, Han A. Koh, James C. M. Ho, Santiago Viteri Ramirez, Alice Tsang Shaw, Glen J. Weiss, Corey J. Langer, Rudolf M. Huber, Myung-Ju Ahn, William G Reichmann, David Kerstein, Victor M. Rivera, D. Ross Camidge. Poster #9060

Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM) Jose Manuel Trigo Perez, Emilie Van Brummelen, Evgeny Levchenko, Manuel Domine, Pilar Garrido Lopez, Hedy L. Kindler, Daniel Morgensztern, Marjorie Glass Zauderer, Johan F. Vansteenkiste, Santiago Viteri Ramirez, Katherine Baker Neblett, Jeffrey Botbyl, Eddie Jose, Adina Zajac, Ionel Mitrica, Robert S. Sikorski, Li Yan. Poster #8557

Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study Jong-Seok Lee, Ji-Youn Han, Myung-Ju Ahn, In-Jae Oh, HyeRyun Kim, Dae Ho Lee, Erin Marie Bertino, Santiago Viteri Ramirez, Nathan A. Pennell, Antoinette J. Wozniak, Joan H. Schiller, Chester Lin, Harold N. Keer, Mohammad Azab, Benjamin Besse, D. Ross Camidge. Poster #9059

Selective CHK1 inhibition as a therapeutic approach in NSCLC, a new option for KRAS mutated patients and squamous cell carcinoma Daniela Morales-Espinosa, Silvia García-Román, Miguel Angel Molina-Vila, Ana Gimenez Capitan, Jordi Bertran-Alamillo, Pedro Mendez, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell. Poster #169740

EGFR  mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer Silvia Calabuig-Fariñas, Eloisa Jantus-Lewintre, Clara Mayo-de las Casas, Nuria Jordana-Ariza, Ariadna Balada, Ana Blasco, Miguel Angel Molina-Vila, Rafael Rosell, Carlos Camps. Proceedings #169534